Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?[J].Annals of allergy, asthma, and immunology 2015,2(2).ChiaraTontini, LuciaMarinangeli, MiriamCognigni, Maria BeatriceBilò, LeonardoAntonicelli. (2015) Omalizumab in chronic spontaneous urticaria: patient-...
XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat chronic spontaneous urticaria (CSU, previously referred to as chronic idiopathic urticaria (CIU), chronic hives without a known cause) in people 12 years of age and older who continue to have hives th...
Chronic spontaneous urticaria (CSU) poses significant challenges, especially in pediatric and adolescent patients, impacting physical, emotional, and social well-being. Recent biologic breakthroughs offer promise, however, data on safety and efficacy in this population remain limited. ...
Omalizumab therapy is effective and safe in patients with chronic spontaneous urticaria (CSU) resistant to nonsedating histamine1 (H1) antihistamines (nsAHs).To evaluate the efficacy and safety of omalizumab in elderly (aged ≥65 years) patients with nonsedating H1-antihistamine-refractory CSU in ...
Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb's mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune ur...
Conclusion: Our observations support the findings in the literature indicating that omalizumab is an effective and safe option in the management of treatment-resistant chronic urticaria. Keywords:Chronic spontaneous urticaria, chronic urticaria, omalizumab, anti-IgE, treatment ...
Omalizumab (OMA) is highly effective for refractory chronic spontaneous urticaria (CSU), but its high cost exerts a great economic burden on patients and society. Current knowledge is lacking regarding the economic impact of long-term administration of OMA on patients with CSU in the real-world ...
It can occur as a complication of chronic spontaneous urticaria (CSU). In idiopathic anaphylaxis presenting with frequent attacks, long-term prophylaxis with H1antihistamines and steroid treatment is recommended but rarely effective. Omalizumab, a humanized monoclonal antibody drug that decreases free ...
understanding why ligelizumab exerts a qualitatively and functionally distinct inhibition profile from omalizumab and is superior in suppressing FcεRI-dependent allergic reactions in vitro, in a passive systemic anaphylaxis mouse model in vivo and in clinical studies with chronic spontaneous urticaria ...
Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumabdoi:10.1111/all.13586Weller KarstenOhanyan TatevikHawro TomaszEllrich AndréSussman GordonKoplowitz JakeGimenez-Arnau Ana MariaPeveling-Oberhag Adriane...